Please note that the following document was created by the former Australian Council for Safety and Quality in Health Care. The former Council ceased its activities on 31 December 2005 and the Australian Commission for Safety and Quality in Health Care assumed responsibility for many of the former Council’s documents and initiatives. Therefore contact details for the former Council listed within the attached document are no longer valid.

The Australian Commission on Safety and Quality in Health Care can be contacted through its website at http://www.safetyandquality.gov.au/ or by email mail@safetyandquality.gov.au

Note that the following document is copyright, details of which are provided on the next page.
The Australian Commission for Safety and Quality in Health Care was established in January 2006. It does not print, nor make available printed copies of, former Council publications. It does, however, encourage not for profit reproduction of former Council documents available on its website.

Apart from not for profit reproduction, and any other use as permitted under the Copyright Act 1968, no part of former Council documents may be reproduced by any process without prior written permission from the Commonwealth available from the Department of Communications, Information Technology and the Arts. Requests and enquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Intellectual Copyright Branch, Department of Communications, Information Technology and the Arts, GPO Box 2154, Canberra ACT 2601 or posted at http://www.dcita.gov.au/cca
**Index**

**Section 1: Hypokalaemia**
- Clinical Signs of Potassium Deficit 2
- Considerations in Potassium Replacement 2
- Magnitude of Potassium Deficit 2
- Methods and Rate of Potassium Replacement 3
- Guidelines for Potassium Replacement 4
- Considerations for Parenteral Potassium Administration 4
- Safe Preparation of Parenteral Potassium Solutions 4
- Potassium Preparations Available at RHH 4
- Storage and Availability of Potassium 5

**Section 2: Hyperkalaemia**
- Causes of Hyperkalaemia 6
- Clinical features of Hyperkalaemia 6
- ECG Changes with Hyperkalaemia 6
- Treatment of Severe Hyperkalaemia 6
- Resonium A® (Sodium polystyrene sulphonate) 7

**Section 3: References** 7

These guidelines were produced by the Pharmacy Department, Royal Hobart Hospital in consultation with Associate Professor Anthony Bell and Associate Professor Janet Vial.

Further copies of these guidelines may be obtained from the Drug Information Centre 03 6222 8737.

Comments relating to these guidelines should be forwarded to Sarah Herd via email: sarah.herd@dhhs.tas.gov.au

Disclaimer: This document has been developed by the Royal Hobart Hospital specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at their own risk and the Royal Hobart Hospital assumes no responsibility whatsoever.
Potassium is the major positive ion in intracellular fluid and is essential for maintenance of:
- Electropotential gradient of the cell membrane
- Isotonicity
- Acid-base balance
The kidney has a major role in potassium homeostasis.

The reference range for serum potassium is 3.5 – 5.0 mmol/L.

**Section 1: Hypokalaemia**

**Clinical Signs of Potassium Deficit**
Signs and symptoms of potassium deficit are late and non-specific including:
- Apathy
- Weakness
- Cramping
- Paraesthesia
- Heart rhythm disturbance (common) - ECG showing sagging ST segments, depression of T waves and elevated U waves
- Muscle paralysis (late sign)

**Considerations in Potassium Replacement**
- Hypokalaemia may be corrected either orally or parenterally.
- Oral is the preferred route of administration for potassium replacement, as it is easy to administer and readily absorbed from the GI tract.
- Replacement fluid volume is a major issue during parenteral potassium replacement (as one litre per hour IV fluid is not appropriate in the usual clinical setting).
- Assess the fluid balance if large volumes of potassium replacement are given via the peripheral route.
- Use extreme caution when replacing potassium in low bodyweight patients.

<table>
<thead>
<tr>
<th>Serum Potassium (mmol/L)</th>
<th>Potassium Deficit (mmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>200</td>
</tr>
<tr>
<td>2.5</td>
<td>300</td>
</tr>
<tr>
<td>2</td>
<td>400</td>
</tr>
<tr>
<td>1.5 (near lethal)</td>
<td>400+</td>
</tr>
</tbody>
</table>

**Magnitude of Potassium Deficit**
Use serum potassium plus ongoing losses to calculate the magnitude of the total body potassium deficit as detailed in the following tables:

<table>
<thead>
<tr>
<th>Ongoing Loss</th>
<th>Amount of Potassium per litre of loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine</td>
<td>20mmol/L (minimum)</td>
</tr>
<tr>
<td>Diuretics</td>
<td>75-100mmol/L of urine</td>
</tr>
<tr>
<td>Alkalosis</td>
<td>75-100mmol/L of urine</td>
</tr>
<tr>
<td>Gut loss (diarrhoea/vomiting)</td>
<td>40mmol/L of GIT loss</td>
</tr>
<tr>
<td>Pancreatic or small bowel fistula</td>
<td>100mmol/L of fluid loss</td>
</tr>
</tbody>
</table>

**TOTAL BODY POTASSIUM DEFICIT**

**Methods and Rate of Potassium Replacement**
Calculate Total Body Potassium Deficit as above, then:

Replace 50 –75% of total body deficit in 24 hrs.

Aim to replace 25% of the total body deficit in the first 6 hours.
### Guidelines for Potassium Replacement

<table>
<thead>
<tr>
<th>Deficit Level</th>
<th>Serum K⁺</th>
<th>Description</th>
<th>Intravenous Administration</th>
<th>Oral Administration</th>
</tr>
</thead>
</table>
| **Critical Deficit** (>400 mmol deficit) | < 2.0 mmol/L | Critical emergency - Admit to ICU/HDU/CCU  
Administer potassium under continuous ECG monitoring. Use IV and oral replacement (if oral route possible):  
IV: 40mmol K⁺ ion (usually chloride) in 100mL IV fluid over 1 hour via central vein  
(if an emergency, a large cubital fossa vein may be used until a central line can be placed)  
Oral: 28 – 42 mmol K⁺ (if possible) every 2 to 4 hours if tolerated (dissolved in 100-150mL water)  
Continue to measure serum potassium every 1 to 2 hours and replace until K⁺ > 2.8 mmol/L | IV: 40mmol K⁺ ion (usually chloride) in 100mL IV fluid over 1 hour via central vein (in an emergency, a large cubital fossa vein may be used until a central line can be placed)  
Oral: 28 – 42 mmol K⁺ (if possible) every 2 to 4 hours if tolerated (dissolved in 100-150mL water) |  |
| **Severe Deficit** (400 mmol deficit) | 2.0 – 2.5 mmol/L | Consider ICU/HDU Admission  
IV and oral replacement  
IV: 20 - 30mmol K⁺ ion (chloride) in 100mL IV fluid over 1 hour via central vein  
(may use fast flowing cubital fossa vein, when K⁺ concentration is 20mmol/100mL)  
Continue to measure serum potassium every 1 to 2 hours until K⁺ > 2.8 mmol/L  
Oral: Two Chlorvescent® tablets (28mmol K⁺) per hour if tolerated (dissolved in 100-150mL water) | IV: 20 - 30mmol K⁺ ion (chloride) in 100mL IV fluid over 1 hour via central vein  
(may use fast flowing cubital fossa vein, when K⁺ concentration is 20mmol/100mL)  
Oral: Two Chlorvescent® tablets (28mmol K⁺) per hour if tolerated (dissolved in 100-150mL water) |  |
| **Moderate Deficit** (200-300 mmol deficit) | 2.5 - 3.0 mmol/L | Oral (preferred) or IV replacement  
Oral: Two Chlorvescent® tablets (28mmol K⁺) three times a day (dissolved in 100-150mL water)  
IV: 30mmol K⁺/litre IV premixed bag at rate of 5-10mmol per hour. Repeat until serum potassium >3.2mmol/L | Oral (preferred) or IV replacement  
Oral: Two Chlorvescent® tablets (28mmol K⁺) three times a day (dissolved in 100-150mL water) |  |
| **Mild Deficit** (150mmol deficit) | 3.0 - 3.5 mmol/L | Oral: Two Chlorvescent® tablets (28mmol K⁺) three times a day (dissolved in 100-150mL water) | Oral: Two Chlorvescent® tablets (28mmol K⁺) three times a day (dissolved in 100-150mL water) |  |

### Considerations for Parenteral Potassium Administration

- Potassium salts **MUST NEVER** be given IM or as an IV push.
- Rapid intravenous administration of potassium is **NOT** recommended. (this can cause a high extracellular K⁺ level and in the presence of a low intracellular K⁺ level, the large change in the cellular electrochemical gradient can lead to death).

### Ward Situation

- Rate of IV potassium should never exceed **30mmol K⁺/hour** without continuous ECG monitoring.  
  **See Guidelines for Potassium Replacement**

### Intensive Care/High Dependency Setting

- Rate of IV potassium should not exceed **40mmol K⁺/hour** in ICU/HDU with continuous ECG monitoring, except in exceptional circumstances.
Safe Preparation of Parenteral Potassium Solutions

If preparing an IV infusion by adding potassium chloride or any other salt of potassium, the resultant solution should be mixed well.

The bag should be fully inverted 10 times to ensure adequate mixing.

DO NOT add potassium to hanging IV bags.

Compatible Fluids: Dextrose 5%, dextrose 10%, sodium chloride 0.9%, sodium chloride 3%, sodium chloride 0.45% and dextrose 5%, Hartmann’s, Dextran 70 in sodium chloride or 5% dextrose

Incompatible Drugs: Adrenaline, Amoxycillin, Amphotericin B, Atropine Sulphate, Cephalothin, Chloramphenicol, Chlorpromazine, Diazepam, Mannitol, Methylprednisolone, Phenytoin, Promethazine, Suxamethonium, Thiopentone

Recommended Parenteral Concentration:

- Potassium salts must be diluted prior to use.
- Peripheral veins are damaged by a potassium concentration of greater than 30mmol/L (3mmol/100mL).
- In an emergency situation a large cubital fossa vein may be used with higher concentration until a central line can be placed.
- Intravenous potassium solutions MUST be administered via a volumetric pump.

Potassium Preparations Available at RHH

<table>
<thead>
<tr>
<th>ORAL POTASSIUM PREPARATIONS</th>
<th>Amount of Potassium contained in Each Unit Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium Chloride 600mg (Slow K®, KSR®, Span K®)</td>
<td>8 mmol K⁺ per tablet</td>
</tr>
<tr>
<td>Potassium Chloride Effervescent (Chlorvescent®)</td>
<td>14 mmol K⁺ per tablet</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARENTERAL POTASSIUM PREPARATIONS</th>
<th>Amount of Potassium contained in Each Unit Dose</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PREMIXED INTRAVENOUS BAGS</th>
<th>Amount of Potassium contained in Each Unit Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium Chloride 30mmol in 1L 0.9% sodium chloride</td>
<td>30mmol K⁺ in 1 Litre</td>
</tr>
<tr>
<td>Potassium Chloride 30mmol in 1L 5% dextrose</td>
<td>30mmol K⁺ in 1 Litre</td>
</tr>
<tr>
<td>Potassium Chloride 30mmol in 1L 4% dextrose &amp; 0.18% sodium chloride</td>
<td>30mmol K⁺ in 1 Litre</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POTASSIUM INJECTIONS</th>
<th>Amount of Potassium contained in Each Unit Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium Chloride 7.5% (1mmol/mL), 10mL injection</td>
<td>10mmol K⁺ in 10mL</td>
</tr>
<tr>
<td>Potassium Chloride 15% (2mmol/mL), 10mL injection (Pharmacy Stock Only)</td>
<td>20mmol K⁺ in 10mL</td>
</tr>
<tr>
<td>Potassium Dihydrogen Phosphate 1mmol/mL, 10mL injection (Note: 10mmol phosphate ion per 10mL)</td>
<td>10mmol K⁺ in 10mL</td>
</tr>
<tr>
<td>Potassium Dihydrogen/Di potassium phosphate 2.5mmol/mL 10mL injection (Note: 14.5mmol phosphate ion per 10mL)</td>
<td>25mmol K⁺ in 10mL</td>
</tr>
</tbody>
</table>

Phosphate Replacement:

- Parenteral phosphate preparations often contain significant amounts of potassium ions.
- CHECK amount of potassium contained in phosphate replacement solution - Rate of infusion for phosphate replacement will be determined by the amount of potassium in the solution.

Consider using a sodium based phosphate replacement solution
Storage and Availability of Potassium

For information regarding Storage and Availability of Potassium Injection refer to RHH Policy and Procedure.

Premixed IV Bags
Premixed IV bags containing 30mmol Potassium Chloride in 1L infusion fluid (0.9% sodium chloride, 5% dextrose or 4% dextrose and 0.18% normal saline) are stocked on the imprest of most wards in the hospital.

The premixed potassium bags are easily distinguished from other IV fluids, as they are packaged in a pink outer bag, with labelling in red writing.

*The premixed potassium IV bags must be stored separately from other types of IV fluid stocked on the ward.*

NO ADDITIVES (including extra potassium) are permitted into premixed solutions.

Potassium Injections
Potassium Chloride 7.5% (10mmol K⁺/10mL) injection is permitted on the imprest of selected wards only. Refer to RHH Procedure for a list of wards permitted to stock potassium chloride 7.5% injection.

Potassium Chloride 7.5% ampoules stocked on wards will be stored in the following manner:

- Physically separated from Water for Injection and 0.9% Sodium Chloride ampoules in all working areas;
- Stored in a labelled locked box, with the label stating:

Potassium Injection: Concentrated Solution. Dilute Before Use

The Pharmacy Department will supply potassium chloride injection for concentrations other than the premixed bags during the normal working hours. A patient specific prescription must be supplied to Pharmacy.

For supply after hours, the requesting ward must obtain the potassium chloride concentrated injection through the After Hours Nurse Supervisor.
Section 2: Hyperkalaemia

Hyperkalaemia may be defined as a serum potassium of greater than 5.0 mmol/L.

Causes of Hyperkalaemia

- Artifactual (sampling errors)
- Excessive intake
- Severe tissue damage
- Decreased excretion (caused by renal failure or by drugs, for example; ACE Inhibitors, AT-II antagonists, spironolactone)
- Body fluid compartment shift (for example, acidosis)

Clinical features of Hyperkalaemia

- Tingling
- Paraesthesia
- Weakness
- Hypotension
- Bradycardia
- ECG Changes

ECG Changes with Hyperkalaemia

- Severity of hyperkalaemia determined by the presence of ECG changes.
- The characteristic ECG effects include:
  - Serum $K^+$ 5.5 – 7.0 mmol/L - tall peak T waves
  - Serum $K^+$ > 7.0 mmol/L - widening QRS complex, P waves disappear
  - Serum $K^+$ > 8.0 mmol/L – sine wave rhythm

Treatment of Severe Hyperkalaemia

Treatment of hyperkalaemia is directed at the underlying cause.

<table>
<thead>
<tr>
<th>Hyperkalaemia</th>
<th>Serum $K^+$ &gt; 5.0 mmol/L</th>
</tr>
</thead>
</table>

ECG Changes

- ECG changes include:
  - Serum $K^+$ 5.5 – 7.0 mmol/L - tall peak T waves
  - Serum $K^+$ > 7.0 mmol/L - widening QRS complex, P waves disappear
  - Serum $K^+$ > 8.0 mmol/L – sine wave rhythm

Emergency Treatment [Temporary Measures Only - Do Not Delay Definitive Treatments]*

1. **Insulin:** Administer IV 10 units of soluble insulin (Actrapid®) in 50mL of 50% dextrose over 15 minutes. (Onset: 20-30 minutes)

2. **CaCl₂:** Initiate IV calcium chloride 5ml of 10% (3.4 mmol) as an IV push over 2-3 mins into a large vein, in attempt to prevent arrest. Repeat until ECG improves and consider transfer to ICU/HDU. (Onset: <5 minutes, duration: 30-60 minutes)

3. **If acidotic:** Administer IV sodium bicarbonate 25 - 50 mmol (25-50ml of 8.4% sodium bicarbonate) over 15 minutes. (Onset: <5 minutes, duration: 15-30 minutes)

Definitive Treatments

1. **Diuretics:** Administer a loop diuretic (frusemide) IV at a dose appropriate for the renal function. (Onset: 1 hour)

2. **Dialysis:** The excess total body potassium must be removed by either the intrinsic renal function or dialysis. Do not delay – other methods of control are temporary.

*Resonium is not appropriate therapy for severe hyperkalaemia
Resonium A® (Sodium polystyrene sulphonate)

Place in Therapy

- The role of Resonium A® in the emergency setting is limited as the biochemical effects take several hours.
- It is advised that Resonium A® NOT be used to treat symptomatic hyperkalaemia. Use should be limited to treatment of asymptomatic hyperkalaemia in the chronic setting e.g. chronic renal failure.

Mechanism of Action

- Sodium ions are exchanged for potassium ions and the exchanged resin is excreted via the faeces
- 15g of Resonium A® lowers serum potassium by ~0.1mmol/L.

Administration

- Oral: 15g up to four times a day dispersed in water (50-100mL).
- Rectal: 30g up to every six hours dispersed in water to 100mL. The enema should be retained for as long as possible (ie. 6 to 9 hours).

Following retention of rectal Resonium A®, a colonic irrigation with a non-sodium, non-potassium containing solution is advised to ensure adequate removal of the resin, for example, 5% dextrose 100mL.

Adverse Effects

- Anorexia
- Nausea
- Vomiting
- Constipation
- Colonic necrosis (rectal administration)

Availability

- Prepacks of Resonium A® for oral or rectal administration are available from Pharmacy on prescription.
- Oral and Rectal Prepacks are also available in the After Hours Pharmacy (Refer to After Hours Nurse Manager for access).

Section 3: References

Saggar-Malik AK, Cappuccio FP. Potassium supplements and potassium-sparing diuretics. A review and guide to appropriate use. Drugs 1993; 46 (6): 986-1008
Subject: Intravenous Administration of Potassium Chloride

Effective Date: Date when policy is implemented
Review Date: Date when policy is up for review e.g. Two yearly
Approved by: Royal Hobart Hospital Management Committee or Continuum of Care Committee

Primary Responsibilities: Nursing, Pharmacy and Medical Staff

Preamble:
Potassium chloride concentrated injection and other strong potassium solutions can be fatal if administered inappropriately. Research into common medication errors has identified potassium chloride concentrated injection as a potential high risk for patient safety.

Policy:
To reduce the potential for medication error by the following measures:

1. Premixed potassium intravenous infusion bags are to be used for all intravenous potassium administration unless it is clinically inappropriate;
2. Premixed potassium intravenous infusion bags to be available as imprest items on all wards requiring potassium;
3. No additional potassium to be added to the premixed potassium bags;
4. Availability of potassium chloride concentrated injection at ward level to be restricted;
5. Any potassium chloride concentrated injection stored on wards must be kept in a locked receptacle and separated from normal saline and water for injection ampoules.
6. Current potassium prescribing and administration guidelines to be accessible in all wards and departments where potassium administration may be required.

For further information contact
Sarah Herd, Pharmacy Department
Phone: 03 6222 8451 Email: sarah.herd@dhhs.tas.gov.au
Subject: Intravenous Administration of Potassium Chloride

Effective Date: Date when procedure is implemented
Review Date: Date when procedure is up for review e.g. Two Yearly
Approved by: Royal Hobart Hospital Management Committee or Continuum of Care

Primary Responsibilities: Nursing, Pharmacy and Medical Staff

Procedure:

(1) Premixed Intravenous Bags

Premixed IV bags containing 30mmol Potassium Chloride in 1 litre infusion fluid (0.9% sodium chloride, 5% dextrose or 4% dextrose and 0.18% sodium chloride) are imprinted on most wards in the hospital.

Wards stocking the premixed potassium intravenous bags must physically separate these bags from other intravenous fluids. The premixed potassium bags are easily distinguished from other IV fluids, as they are packaged in a pink outer bag, with labelling in red print.

(2) Potassium Chloride 7.5% (10mmol K⁺/10ml) Injection

The following wards ONLY are permitted to stock Potassium Chloride 7.5% injection:

- Department of Critical Care Medicine (ICU and HDU)
- Cardi thoracic Intensive Care Unit (CT-ICU)
- Neurosurgical High Dependency Unit (NSU HDU)
- Cardi thoracic Unit (2DS)
- Oncology (1BS)
- Paediatrics (3A)
- Neonatal Intensive Care (NICU)
- Department of Emergency Medicine (DEM)
- Operating Theatre
- Ward 2BS
- General Surgical (6A)
In all other areas, if concentrated potassium chloride injection is required, it must be obtained from Pharmacy during normal working hours or via the After Hours Nurse Supervisor. It will only be supplied by Pharmacy on receipt of a copy of the administration order for the potassium chloride infusion.

(3) Storage of Potassium Chloride 7.5% (10mmol K+/10ml) Injection:

Potassium Chloride 7.5% concentrated injection must be stored as follows:
• In the preparation/work room of the ward
• Locked in a receptacle with a label stating: “Potassium Injection: Concentrated Solution. Dilute before Use”
• Physically separated from Water for Injection and 0.9% sodium chloride ampoules

(4) Preparation of Parenteral Potassium Solutions

Potassium chloride concentrated injections should only be added to a bag of infusion fluid if a premixed solution is not clinically appropriate.

If preparing an IV infusion by adding potassium chloride concentrated injection or any other salt of potassium, the following are essential:
• The IV bag should be fully inverted at least 10 times to ensure adequate mixing. The resultant solution must be mixed well before connection to the infusion pump;
• Never add concentrated potassium injection to a hanging bag.
• NO ADDITIVES (including extra potassium) are permitted to premixed potassium solutions;
• All potassium infusions must be administered via a volumetric infusion pump.

(5) Prescribing and Administration Guidelines

The Pharmacy Department be responsible for coordinating the periodic review, updating and production of the Guidelines.

FOR FURTHER INFORMATION CONTACT
Sarah Herd, Pharmacy Department
Phone: 03 6222 8451 Email: sarah.herd@dhhs.tas.gov.au